Literature DB >> 2498251

Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.

S Fujii1, Y Shimamoto, H Ohshimo, T Imaoka, M Motoyama, M Fukushima, T Shirasaka.   

Abstract

The correlations of the 5-fluorouracil (5-FU) level in the plasma and the duration of continuous 5-FU infusion with the antitumor activity of 5-FU on Yoshida sarcomas in rats were examined. The circadian variation in the plasma level of 5-FU during continuous infusion was prevented by treatment with 3-cyano-2,6-dihydroxypyridine (CNDP), which strongly inhibits 5-FU degradation. On continuous venous infusion of 2 to 30 mg/kg of 5-FU over 24 h with CNDP at a molar ratio of 1:10 into normal rats, the 5-FU level in the blood was linearly proportional to the dose of 5-FU. The optimum schedule for antitumor activity on Yoshida sarcomas in rats was found to be infusion of 5-FU at 5 mg/kg over 24 h for 6 consecutive days, which gave a plasma 5-FU level of 176 ng/ml. Continuous infusion of 5-FU to give a plasma level of 300 ng/ml for 6 consecutive days from day 5 after implantation of tumor cells, when the tumors weighed about 1.0 g, resulted in complete regression of the tumors in all rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498251      PMCID: PMC5917696          DOI: 10.1111/j.1349-7006.1989.tb02285.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

1.  Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation.

Authors:  C L Hornbeck; R A Floyd; J E Byfield; J C Griffiths; S Frankel; T R Sharp
Journal:  Cancer Treat Rep       Date:  1982-03

2.  A rapid high-performance liquid chromatographic method for quantitation of 5-fluorouracil in plasma after continuous intravenous infusion.

Authors:  D C Sampson; R M Fox; M H Tattersall; W J Hensley
Journal:  Ann Clin Biochem       Date:  1982-03       Impact factor: 2.057

3.  Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

Authors:  K Tatsumi; M Fukushima; T Shirasaka; S Fujii
Journal:  Jpn J Cancer Res       Date:  1987-07

4.  Protracted ambulatory venous infusion of 5-fluorouracil.

Authors:  J Lokich; N Fine; J Perri; A Bothe
Journal:  Am J Clin Oncol       Date:  1983-02       Impact factor: 2.339

5.  Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol.

Authors:  C Erlichman; S Fine; T Elhakim
Journal:  Cancer Treat Rep       Date:  1986-07

6.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.

Authors:  W E Hull; R E Port; R Herrmann; B Britsch; W Kunz
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

7.  Allopurinol modulation of fluorouracil toxicity.

Authors:  R M Fox; R L Woods; M H Tattersall; A A Piper; D Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Letter: Blood levels of 5-fluorouracil during intravenous infusion.

Authors:  M Kawai; J Rosenfeld; P McCulloch; B L Hillcoat
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

9.  Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.

Authors:  J L Boublil; G Milano; R Khater; J Bourry; A Thyss; J N Bruneton; N Renée; C Philip; M Namer
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

10.  Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.

Authors:  B L Hillcoat; P B McCulloch; A T Figueredo; M H Ehsan; J M Rosenfeld
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

View more
  11 in total

1.  Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.

Authors:  Akira Ono; Tateaki Naito; Haruyasu Murakami; Toshiaki Takahashi; Yukiko Nakamura; Asuka Tsuya; Kyoichi Kaira; Satoshi Igawa; Takehito Shukuya; Takehiro Shukuya; Akihiro Tamiya; Rieko Kaira; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Int J Clin Oncol       Date:  2010-03-04       Impact factor: 3.402

Review 2.  Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.

Authors:  T Shirasaka; S Yamamitsu; A Tsuji; T Taguchi
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 3.  S-1 in gastric cancer: a comprehensive review.

Authors:  Yoshihiko Maehara
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

4.  Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.

Authors:  G A Bjarnason; I G Kerr; N Doyle; M Macdonald; M Sone
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.

Authors:  D P Baccanari; S T Davis; V C Knick; T Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.

Authors:  T Shirasaka; Y Shimamoto; H Ohshimo; H Saito; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Severe adverse effects of 5-fluorouracil in S-1 were lessened by haemodialysis due to elimination of the drug.

Authors:  Kazunori Inoue; Yasuyuki Nagasawa; Ryohei Yamamoto; Hiroki Omori; Tomonori Kimura; Kodo Tomida; Yoshiyuki Furumatsu; Enyu Imai; Yoshitaka Isaka; Hiromi Rakugi
Journal:  NDT Plus       Date:  2008-12-18

8.  S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.

Authors:  Junfei Feng; Jinquan Xu; Xuehui Wang; Dejun Zhao
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

9.  Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line.

Authors:  H Takeda; M Haisa; Y Naomoto; R Kawashima; K Satomoto; T Yamatuji; N Tanaka
Journal:  Jpn J Cancer Res       Date:  1999-06

10.  Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.

Authors:  Y Kimura; H Okuda
Journal:  Jpn J Cancer Res       Date:  1999-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.